| CRLBF Stock | | | USD 1.08 0.01 0.92% |
CEO
Mr. Charles Bachtell is Chief Executive Officer, Director of the Company. Charles Bachtell is the CEO of Cresco Labs, LLC. Bachtell is an attorney and brings with him deep legal expertise in both corporate governance and complex regulatory compliance. Bachtell lead the efforts for Cresco to successfully win and acquire the nineteen licenses that it currently holds and continues to work tirelessly to ensure that Cresco remains an industry leader, setting new standards for a progressive, transparent and reputable medical cannabis community, and operating at all times in a professional, secure and compliant manner. Bachtell is a founding member of the Illinois Cannabis Bar Association and industry trade associations in IL, PA, and OH. Prior to Cresco Labs, Bachtell served for 8 years as the Executive Vice President and General Counsel of Guaranteed Rate, the nations seventh largest mortgage bank a leading attorney during the reform of the US mortgage industry. Bachtell is an adjunct Professor at Northwestern University Pritzker School of Law teaching a course on the legal and regulatory issues in the emerging cannabis industry. since 2019.
| Age | 44 |
| Tenure | 5 years |
| Phone | 312 929 0993 |
| Web | https://www.crescolabs.com |
Cresco Labs Management Efficiency
The company has return on total asset
(ROA) of
0.0399 % which means that it generated a profit of $0.0399 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.0635) %, meaning that it generated substantial loss on money invested by shareholders. Cresco Labs' management efficiency ratios could be used to measure how well Cresco Labs manages its routine affairs as well as how well it operates its assets and liabilities.
Cresco Labs has accumulated 465.08
M in total debt with debt to equity ratio
(D/E) of 0.88, which is about average as compared to similar companies. Cresco Labs has a current ratio of 1.28, suggesting that it
is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Cresco Labs until it has trouble settling it off, either with new capital or with free cash flow. So, Cresco Labs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cresco Labs sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cresco to invest in growth at high rates of return. When we think about Cresco Labs' use of debt, we should always consider it together with cash and equity.
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. The company was founded in 2013 and is headquartered in Chicago, Illinois. Cresco Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 3300 people. Cresco Labs [CRLBF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Cresco Labs Leadership Team
Elected by the shareholders, the Cresco Labs' board of directors comprises two types of representatives: Cresco Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cresco. The board's role is to monitor Cresco Labs' management team and ensure that shareholders' interests are well served. Cresco Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cresco Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Sampson, CoFounder Director | |
| Thomas Manning, Chairman of the Board | |
| Charles Bachtell, CEO, Director | |
| Ty Gent, Chief Officer | |
| John Schetz, G Counsel | |
| Brenna CPA, Treasury Accounting | |
| Zach Marburger, Interim Officer | |
| Jake Graves, Ma Relations | |
| Dennis Olis, Chief Officer | |
| Impola Kelli, VP Compliance | |
Cresco Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cresco Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Cresco OTC Stock
Cresco Labs financial ratios help investors to determine whether Cresco OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cresco with respect to the benefits of owning Cresco Labs security.